According to a recent LinkedIn post from Cytovale, an on-demand webinar features clinicians from Froedtert Hospital and the Medical College of Wisconsin discussing real-world use of IntelliSep, a host-response diagnostic for emergency departments. The post highlights observational data suggesting a 42% reduction in mortality among emergency patients with suspected infection following IntelliSep implementation, as well as workflow and triage insights.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that IntelliSep is being positioned as a tool for earlier sepsis risk stratification, potentially improving emergency department decision-making and operational efficiency. For investors, broader clinical adoption and validation of such outcomes data could support Cytovale’s value proposition in sepsis diagnostics, strengthen its competitive standing in emergency medicine, and underpin future revenue growth if translated into commercial contracts and system-wide deployments.

